APPLICATION
ANDA062772
TYPE
ANDA
ORIGINAL APPROVAL
1993-04-15
LATEST ACTION
2024-05-01
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued, Prescription
Products
AMPICILLIN SODIUMDiscontinued
AMPICILLIN SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMPrescription
AMPICILLIN SODIUM EQ 250MG BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMDiscontinued
AMPICILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMDiscontinued
AMPICILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMPrescription
AMPICILLIN SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMDiscontinued
AMPICILLIN SODIUM EQ 125MG BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMPrescription
AMPICILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMPrescription
AMPICILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
Approval history
2024-05-01Labeling · Supplement 17 · standardAP
2018-02-15Labeling · Supplement 13 · standardAP
2013-05-31Labeling · Supplement 9 · standardAP
2007-07-23Labeling · Supplement 6AP
2007-02-28Labeling · Supplement 4AP
1994-02-14Manufacturing (CMC) · Supplement 1AP
1993-11-05Manufacturing (CMC) · Supplement 2AP
1993-04-15OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.